Synthesis and Biological Evaluation of Cardiac Glycosides for Cancer Therapy by Targeting the DNA Damage Response
Abstract Cardiac glycosides (CGs) are bioactive compounds originally used to treat heart diseases, but recent studies have demonstrated their anticancer activity. We previously demonstrated that Antiaris toxicaria2 (AT2) possesses anticancer activity in KRAS mutated lung cancers via impinging on the DNA damage response (DDR) pathway. Toward developing this class of molecules for cancer therapy, herein we report a multistep synthetic route utilizing k‐strophanthidin as the initial building block for determination of structure–activity relationships (SARs). A systematic structural design approach was applied that included modifications of the sugar moiety, the glycoside linker, stereochemistry, and lactone ring substitutions to generate a library of O‐glycosides and MeON‐neoglycosides derivatives. These molecules were screened for their anticancer activities and their impact on DDR signaling in KRAS mutant lung cancer cells. These results demonstrate the ability to chemically synthesize CG derivatives and define the SARs to optimize AT2 as a cancer therapeutic..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
ChemMedChem - 17(2022), 21 |
| Beteiligte Personen: |
Ainembabazi, Diana [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley‐VCH GmbH |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1002/cmdc.202200415 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003682919 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003682919 | ||
| 003 | DE-627 | ||
| 005 | 20230307131035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cmdc.202200415 |2 doi | |
| 028 | 5 | 2 | |a CMDC_CMDC202200415.xml |
| 035 | |a (DE-627)WLY003682919 | ||
| 035 | |a (WILEY)CMDC202200415 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 540 |a 610 |q ASE |
| 082 | 0 | 4 | |a 540 |a 610 |q ASE |
| 084 | |a 44.42 |2 bkl | ||
| 084 | |a 35.07 |2 bkl | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 1 | |a Ainembabazi, Diana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis and Biological Evaluation of Cardiac Glycosides for Cancer Therapy by Targeting the DNA Damage Response |
| 264 | 1 | |c 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley‐VCH GmbH | ||
| 520 | |a Abstract Cardiac glycosides (CGs) are bioactive compounds originally used to treat heart diseases, but recent studies have demonstrated their anticancer activity. We previously demonstrated that Antiaris toxicaria2 (AT2) possesses anticancer activity in KRAS mutated lung cancers via impinging on the DNA damage response (DDR) pathway. Toward developing this class of molecules for cancer therapy, herein we report a multistep synthetic route utilizing k‐strophanthidin as the initial building block for determination of structure–activity relationships (SARs). A systematic structural design approach was applied that included modifications of the sugar moiety, the glycoside linker, stereochemistry, and lactone ring substitutions to generate a library of O‐glycosides and MeON‐neoglycosides derivatives. These molecules were screened for their anticancer activities and their impact on DDR signaling in KRAS mutant lung cancer cells. These results demonstrate the ability to chemically synthesize CG derivatives and define the SARs to optimize AT2 as a cancer therapeutic. | ||
| 700 | 1 | |a Geng, Xinran |4 aut | |
| 700 | 1 | |a Gavande, Navnath S. |4 aut | |
| 700 | 1 | |a Turchi, John J. |4 aut | |
| 700 | 1 | |a Zhang, Youwei |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |g 17(2022), 21 |w (DE-627)WLY003672778 |x 18607187 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:21 |g extent:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.42 |q ASE |
| 936 | b | k | |a 35.07 |q ASE |
| 936 | b | k | |a 58.28 |q ASE |
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 21 |g 10 | ||